Prognostic impact of serum CYFRA 21-1 among classic tumor markers in patients with non-metastatic but potentially lethal bladder cancer
Sources of Funding: none
Introduction
No serum prognosticator has been established in patients with potentially lethal bladder cancer. The aim of this study is to evaluate the prognostic impact of serum CYFRA 21-1 (CYFRA) in these patients compared with classic tumor markers.
Methods
Serum levels of CYFRA and other classic tumor markers: CA19-9, SCC, and C-reactive protein (CRP) were measured in 66 patients with T1G3 (n = 20) or muscle invasive bladder cancer (n = 46) without metastasis between Jan 2011 and Aug 2015. Cut-off values of the tumor markers were determined by receiver operating characteristic analyses. Prognostic values of age, gender, T stage, hydronephrosis, albumin, hemoglobin, CA19-9, SCC, CRP, and CYFRA were evaluated using multivariate analysis with a Cox proportional hazards model.
Results
The median (range) value of CYFRA was 2.6 (1.1-34) ng/mL. The median follow-up period was 24.3 (1.1-58.1) months. Prognostic values of age (< 73 vs. ≥ 73), T stage (< T2 vs. ≥ T2), hydronephrosis (absence vs. presence), albumin (cut-off 4.0 g/dL, median), hemoglobin (cut-off 12.7 g/dL, median), CA19-9 (cut-off 21 U/mL), SCC (cut-off 1.5 ng/mL), CRP (cut-off 0.1 mg/dL), and CYFRA (cut-off 3.5 ng/mL) were evaluated dichotomously. Multivariate analyses revealed that CYFRA (p = 0.017) was the only significant and independent predictor of cancer-specific survival. Risk of cancer-specific mortality was 4.48-fold (95% CI, 1.37-18.27; p = 0.012) higher in CYFRA-high patients than in CYFRA-low/either classic tumor marker-high patients._x000D_ _x000D_ Figure. Cancer-specific survival curves according to CYFRA and classic tumor markers status
Conclusions
The current results indicated that cancer-specific mortality of non-metastatic bladder cancer could be better predicted by CYFRA than other previously reported tumor markers. Further prospective analyses will be needed to confirm our results.
Funding
none
Kojiro Tachibana
Shunsuke Hiranuma
Hironori Sugiyama
Makoto Kagawa
Hideki Takeshita
Yohei Okada
Makoto Morozumi
Satoru Kawakami